Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10040592 | 0.93 | KCNH2 (0.39) | KCNH2HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL10040565 | 0.89 | SMN1; SMN2 (0.44) | RAB9ANPC1SMOSMN1; SMN2 | |
| SCHEMBL10040570 | 0.87 | FAAH (0.39) | ACKR3KCNH2HCRTR1HCRTR2APLNR | |
| SCHEMBL10040580 | 0.86 | RAB9A (0.40) | ACKR3KCNH2HCRTR1HCRTR2RAB9A | |
| SCHEMBL10040582 | 0.86 | USP7 (0.38) | RAB9ANPC1SMOSMN1; SMN2 | |
| SCHEMBL10040577 | 0.85 | HCRTR1 (0.44) | ACKR3KCNH2HCRTR1HCRTR2RAB9A | |
| SCHEMBL10040586 | 0.85 | KDM4E (0.41) | ACKR3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10040589 | 0.80 | KCNH2 (0.40) | KCNH2HCRTR1HCRTR2APLNRCPT1A | |
| SCHEMBL10040508 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2 | |
| SCHEMBL13513893 | 0.79 | SMO (0.33) | SMOCPT1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | ACKR3 573/4885KCNH2 140/4885HCRTR1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.